<SEC-DOCUMENT>0001564590-20-046049.txt : 20201008
<SEC-HEADER>0001564590-20-046049.hdr.sgml : 20201008
<ACCEPTANCE-DATETIME>20201008070545
ACCESSION NUMBER:		0001564590-20-046049
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20201008
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20201008
DATE AS OF CHANGE:		20201008

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			EyePoint Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001314102
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				262774444
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51122
		FILM NUMBER:		201230098

	BUSINESS ADDRESS:	
		STREET 1:		480 PLEASANT STREET
		STREET 2:		SUITE B300
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472
		BUSINESS PHONE:		617-926-5000

	MAIL ADDRESS:	
		STREET 1:		480 PLEASANT STREET
		STREET 2:		SUITE B300
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	pSivida Corp.
		DATE OF NAME CHANGE:	20080619

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	pSivida LTD
		DATE OF NAME CHANGE:	20050111
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>eypt-8k_20201008.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml  version="1.0" encoding="utf-8"?>
<!-- DFIN ActiveDisclosure(SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2020-10-07T22:08:34.5086892+00:00 -->
<!-- Version            : 5.0.1.513 -->
<!-- Package ID         : a25b535ff2524c3eb3c4bdb2d68560cf -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:eypt="http://eyepointpharma.com/20201008" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2019-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2019-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta http-equiv="Content-Type" content="text/html" />
<title>
eypt-8k_20201008.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body><div style="display:none">
	<ix:header>
		<ix:hidden>
			<ix:nonNumeric id="F_000001" name="dei:AmendmentFlag" contextRef="C_0001314102_20201008_20201008">false</ix:nonNumeric>
			<ix:nonNumeric id="F_000004" name="dei:EntityCentralIndexKey" contextRef="C_0001314102_20201008_20201008">0001314102</ix:nonNumeric>
		</ix:hidden>
		<ix:references>
			<link:schemaRef xlink:type="simple" xlink:href="eypt-20201008.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef>
		</ix:references>
		<ix:resources>
			<xbrli:context id="C_0001314102_20201008_20201008">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-10-08</xbrli:startDate>
					<xbrli:endDate>2020-10-08</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
		</ix:resources>
	</ix:header>
</div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;border-bottom:Double 2.25pt;padding-bottom:1pt;text-indent:0%;font-weight:bold;;font-size:4pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WASHINGTON, DC 20549</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-left:37.73%;margin-right:37.59%;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM <ix:nonNumeric id="F_000000" name="dei:DocumentType" contextRef="C_0001314102_20201008_20201008">8-K</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-left:37.73%;margin-right:37.59%;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CURRENT REPORT </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Section&#160;13 or 15(d) of the </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities Exchange Act of 1934 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date of report (Date of earliest event reported): <ix:nonNumeric id="F_000002" name="dei:DocumentPeriodEndDate" contextRef="C_0001314102_20201008_20201008" format="ixt:datemonthdayyearen">October 8, 2020</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-left:37.73%;margin-right:37.59%;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000003" name="dei:EntityRegistrantName" contextRef="C_0001314102_20201008_20201008">EyePoint Pharmaceuticals, Inc.</ix:nonNumeric> </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Exact Name of Registrant as Specified in Charter)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-left:37.73%;margin-right:37.59%;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="width:34.02%;"></td>
<td style="width:1%;"></td>
<td style="width:31.99%;"></td>
<td style="width:1%;"></td>
<td style="width:31.99%;"></td>
</tr>
<tr>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000015" name="dei:EntityIncorporationStateCountryCode" contextRef="C_0001314102_20201008_20201008" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000007" name="dei:EntityFileNumber" contextRef="C_0001314102_20201008_20201008">000-51122</ix:nonNumeric></p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000008" name="dei:EntityTaxIdentificationNumber" contextRef="C_0001314102_20201008_20201008">26-2774444</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or Other Jurisdiction</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of Incorporation)</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Commission</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">File Number)</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(I.R.S. Employer</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000009" name="dei:EntityAddressAddressLine1" contextRef="C_0001314102_20201008_20201008">480 Pleasant Street</ix:nonNumeric> </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000010" name="dei:EntityAddressCityOrTown" contextRef="C_0001314102_20201008_20201008">Watertown</ix:nonNumeric>, <ix:nonNumeric id="F_000011" name="dei:EntityAddressStateOrProvince" contextRef="C_0001314102_20201008_20201008">MA</ix:nonNumeric> <ix:nonNumeric id="F_000012" name="dei:EntityAddressPostalZipCode" contextRef="C_0001314102_20201008_20201008">02472</ix:nonNumeric> </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of Principal Executive Offices, and Zip Code) </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000013" name="dei:CityAreaCode" contextRef="C_0001314102_20201008_20201008">(617)</ix:nonNumeric> <ix:nonNumeric id="F_000014" name="dei:LocalPhoneNumber" contextRef="C_0001314102_20201008_20201008">926-5000</ix:nonNumeric> </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Registrant&#8217;s Telephone Number, Including Area Code </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Former Name or Former Address, if Changed Since Last Report)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-left:37.73%;margin-right:37.59%;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.66%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000018" name="dei:WrittenCommunications" contextRef="C_0001314102_20201008_20201008" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.66%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000019" name="dei:SolicitingMaterial" contextRef="C_0001314102_20201008_20201008" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.66%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000020" name="dei:PreCommencementTenderOffer" contextRef="C_0001314102_20201008_20201008" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.66%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000021" name="dei:PreCommencementIssuerTenderOffer" contextRef="C_0001314102_20201008_20201008" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(b) of the Act: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="width:34.2%;"></td>
<td style="width:1%;"></td>
<td style="width:31.9%;"></td>
<td style="width:1%;"></td>
<td style="width:31.9%;"></td>
</tr>
<tr>
<td valign="bottom" style=" border-bottom:solid 1pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title of</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">each class</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Trading</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Symbol(s)</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name of each exchange</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">on which registered</p></td>
</tr>
<tr>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000016" name="dei:Security12bTitle" contextRef="C_0001314102_20201008_20201008">Common Stock, par value $0.001</ix:nonNumeric></p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000005" name="dei:TradingSymbol" contextRef="C_0001314102_20201008_20201008">EYPT</ix:nonNumeric></p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000017" name="dei:SecurityExchangeName" contextRef="C_0001314102_20201008_20201008" format="ixt-sec:exchnameen">The Nasdaq Stock Market LLC</ix:nonNumeric></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR &#167;240.12b-2). </p>
<p style="text-align:right;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company&#160;&#160;<span style="font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000006" name="dei:EntityEmergingGrowthCompany" contextRef="C_0001314102_20201008_20201008" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span> </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span> </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;border-bottom:Double 2.25pt;padding-bottom:1pt;text-indent:0%;font-weight:bold;;font-size:4pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:left;margin-top:10pt;border-top:none 0pt;padding-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="FIS_CHANGE_IN_DIRECTORS_OR_PRINCIPAL_OFF"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.0</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">. </span><span style="margin-left:49pt;"></span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Entry Into a Material Definitive Agreement.</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 8, 2020, EyePoint Pharmaceuticals, Inc. (the &#8220;Company&#8221;), entered into Amendment No. 2 and Waiver to the Term Loan Agreement (the &#8220;Amendment&#8221;), among the Company, as borrower, EyePoint Pharmaceuticals US, Inc. and Icon Bioscience, Inc., as subsidiary guarantors (the &#8220;Guarantors&#8221;), to its existing debt facility, dated February 13, 2019,<span style="color:#000000;"> and as amended or otherwise modified from time to time,</span> (the &#8220;Loan Agreement&#8221;), with CRG Servicing LLC <span style="Background-color:#FFFFFF;">as administrative agent and collateral agent (the &#8220;CRG&#8221;), and the lenders party to the Loan Agreement</span>. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the Amendment, CRG under the terms of the Loan Agreement (i) waived the financial covenant associated with the Company&#8217;s revenue derived from sales of its products, DEXYCU<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> and YUTIQ<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>, for the twelve-month period ending December 31, 2020 and (ii) amended the financial covenant associated with the Company&#8217;s minimum product revenue to $45 million from $80 million, for the twelve-month period ending December 31, 2021. There were no other material changes to the Loan Agreement.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Amendment, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:18pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:9%;"></td>
<td style="width:91%;"></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;8.01.</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.5pt;;text-indent:-5.5pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other Events. </p></td>
</tr>
</table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 8, 2020, the Company issued a press release announcing the execution of the Waiver.&#160;A copy of the press release, which is filed with this Current Report on Form 8-K as Exhibit 99.1, is hereby filed pursuant to this Item 8.01. </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9.01.&#160;<span style="margin-left:49pt;"></span>Financial Statements and Exhibits. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(d) Exhibits. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:9.94%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit&#160;No.</p></td>
<td valign="bottom" style="width:2%;">
<p style="line-height:2pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:88.06%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" style="width:9.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:90.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="bottom" style="width:2%;">
<p style="line-height:2pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:88.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="eypt-ex101_7.htm"><span style="text-decoration:underline;">Amendment No. 2 and Waiver To Term Loan Agreement, dated October 8, 2020, among EyePoint Pharmaceuticals, Inc. as Borrower, EyePoint Pharmaceuticals US, Inc. and Icon Bioscience, Inc., as subsidiary guarantors and CRG Servicing LLC, as Administrative Agent and Collateral Agent</span></a><span style="text-decoration:underline;">.</span></p></td>
</tr>
<tr>
<td valign="top" style="width:9.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.1</p></td>
<td valign="bottom" style="width:2%;">
<p style="line-height:2pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:88.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="eypt-ex991_6.htm"><span style="text-decoration:underline;">Press Release of EyePoint Pharmaceuticals, Inc., dated October 8, 2020</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
</tr>
<tr>
<td valign="top" style="width:9.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
<td valign="bottom" style="width:2%;">
<p style="line-height:2pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cover Page Interactive Data File (embedded within the inline XBRL document).</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SIGNATURES </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:99.96%;">
<tr>
<td valign="top" style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top" style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;">EyePoint Pharmaceuticals, Inc.</p></td>
</tr>
<tr style="height:12pt;">
<td valign="middle" style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td colspan="4" valign="middle" style="width:51%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:49%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: October 8, 2020</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:43.98%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ George O. Elston</p></td>
</tr>
<tr>
<td valign="top" style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:43.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">George O. Elston</p></td>
</tr>
<tr>
<td valign="top" style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:43.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer and Head of Corporate Development</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>eypt-ex101_7.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
eypt-ex101_7.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;text-transform:none;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_cp_text_1_36"></a><a name="_cp_text_1_45"></a><a name="_cp_text_1_51"></a><a name="_cp_text_1_57"></a><font style="Background-color:#FFFFFF;">Exhibit 10.1</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">AMENDMENT No. 2 and Waiver TO TERM LOAN AGREEMENT </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">THIS AMENDMENT NO. 2 AND WAIVER TO TERM LOAN AGREEMENT, dated as of October 8, 2020 (this &#8220;<font style="font-weight:bold;font-style:italic;">Amendment</font>&#8221;) is made among EYEPOINT PHARMACEUTICALS, INC., a Delaware corporation (the &#8220;<font style="font-weight:bold;font-style:italic;">Borrower</font>&#8221;), the other Obligors party hereto, CRG SERVICING LLC, as administrative agent and collateral agent (in such capacities, &#8220;<font style="font-weight:bold;font-style:italic;">Administrative Agent</font>&#8221;) and the lenders listed on the signature pages hereof (collectively, the &#8220;Lenders&#8221;), with respect to the Loan Agreement referred to below.</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">RECITALS</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, Borrower, Administrative Agent and the Lenders are parties to the Term Loan Agreement, dated as of February 13, 2019, with the Guarantors from time to time party thereto (as amended by the Amendment, Consent, and Waiver to Term Loan Agreement, dated as of August 19, 2020, and as modified by the Waiver to Term Loan Agreement, dated as of November 19, 2019, as further modified by the Consent to Acquisition, dated as of January 31, 2020, and as further modified by the Consent, dated as of April 22, 2020, and as amended and restated, modified or supplemented from time to time, the &#8220;<font style="font-weight:bold;font-style:italic;">Loan Agreement</font>&#8221;); </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, Borrower has requested that Administrative Agent and the Lenders (which Lenders constitute the Majority Lenders party to the Loan Agreement as required by <font style="font-weight:bold;">Section 13.04</font> of the Loan Agreement), and Administrative Agent and the Lenders have agreed to, (i) amend the Minimum Required Revenue covenant set forth <font style="font-weight:bold;">Section 10.02(c) </font>of the Loan Agreement,<font style="font-weight:bold;"> </font>and (ii) waive Borrower&#8217;s requirement to comply with the Minimum Required Revenue covenant set forth in <font style="font-weight:bold;">Section 10.02(b) </font>of the Loan Agreement.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOW, THEREFORE, in consideration of the mutual agreements, provisions and covenants contained herein, the parties agree as follows:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">SECTION 1.<font style="margin-left:36pt;"></font>Definitions; Interpretation<font style="font-weight:normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Terms Defined in Loan Agreement</font>.&nbsp;&nbsp;All capitalized terms used in this Amendment (including in the recitals hereof) and not otherwise defined herein shall have the meanings assigned to them in the Loan Agreement.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">(b)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Interpretation</font>.&nbsp;&nbsp;The rules of interpretation set forth in <font style="font-weight:bold;">Section 1.03</font> of the Loan Agreement shall be applicable to this Amendment and are incorporated herein by this reference.</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_cp_blt_2_10"></a><a name="_cp_text_1_9"></a>SECTION 2.<font style="margin-left:36pt;"></font>Amendments to Loan Agreement<font style="font-weight:normal;">. Subject to </font>Section 4 <font style="font-weight:normal;"><a name="_cp_blt_2_10"></a><a name="_cp_text_1_9"></a>of this Amendment, the Loan Agreement is hereby amended as follows:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_cp_blt_2_16"></a><a name="_cp_text_1_11"></a><a name="_cp_blt_2_22"></a><a name="_cp_text_1_21"></a>(a)<font style="margin-left:36pt;"><a name="_cp_blt_2_22"></a><a name="_cp_text_1_21"></a></font><font style="font-weight:bold;">Section 10.02(c)</font> of the Loan Agreement is hereby amended and restated in its entirety as follows: <font style="margin-left:36pt;"></font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">&#8220;(c)<font style="font-weight:bold;margin-left:36pt;"></font>for the twelve-month period beginning on January 1, 2021 and ending on December 31, 2021, of at least $45,000,000.&#8221;</p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">234986339 v1</strike></font><font style="font-size:12pt;color:#000000;"> </font></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_cp_blt_2_24"></a><a name="_cp_blt_2_25"></a><a name="_cp_blt_2_28"></a><a name="_Ref_ContractCompanion_9kb9Ur013"></a><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-weight:bold;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">SECTION 3.</font><font style="margin-left:36pt;"></font><font style="font-weight:bold;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">Waiver</font><font style="font-weight:normal;">. </font><font style="font-weight:normal;">Subject to </font><font style="font-weight:bold;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">Section </font><font style="font-weight:bold;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">4</font><font style="font-weight:normal;">, </font><font style="font-weight:normal;">Administrative Agent and the Lenders hereby waive Borrower&#8217;s requirement to comply with the Minimum Required Revenue covenant set forth in </font><font style="font-weight:bold;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">Section 10.02(b</font><font style="font-weight:bold;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">)</font><font style="font-weight:normal;"> of the Loan Agreement</font><font style="font-weight:normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">SECTION 4.<font style="margin-left:36pt;"></font>Conditions of Effectiveness<font style="font-weight:normal;">. The effectiveness of </font>Sections 2 <font style="font-weight:normal;">and</font> 3 <font style="font-weight:normal;">of this Amendment shall be subject to the following conditions precedent:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">(a)<font style="margin-left:36pt;"></font>Borrower, the Guarantors, Administrative Agent and the Lenders shall have duly executed and delivered this Amendment; provided, however, that this Amendment shall have no binding force or effect unless all conditions set forth in this <font style="font-weight:bold;">Section 4 </font>have been satisfied; </p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">(b)<font style="margin-left:36pt;"></font>The representations and warranties in <font style="font-weight:bold;">Section 5</font> shall be true in all material respects on the date hereof and on the date on which each of the foregoing conditions is satisfied; and</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">(c)<font style="margin-left:36pt;"></font>The Borrower shall have paid or reimbursed Administrative Agent and Lenders for their reasonable out of pocket costs and expenses incurred in connection with this Amendment, including Administrative Agent and Lenders&#8217; reasonable and documented out of pocket legal fees and costs, pursuant to <font style="font-weight:bold;">Section 13.03(a)(i)(z) </font>of the Loan Agreement.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">SECTION 5.<font style="margin-left:36pt;"></font>Representations and Warranties; Reaffirmation<font style="font-weight:normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">(a)<font style="margin-left:36pt;"></font>Borrower hereby represents and warrants to each Lender as follows:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">(i)<font style="margin-left:36pt;"></font>The Borrower has full power, authority and legal right to make and perform this Amendment.&nbsp;&nbsp;This Amendment is within the Borrower&#8217;s corporate powers and has been duly authorized by all necessary corporate and, if required, by all necessary shareholder action.&nbsp;&nbsp;This Amendment has been duly executed and delivered by the Borrower and constitutes a legal, valid and binding obligation of the Borrower, enforceable against the Borrower in accordance with its terms, except as such enforceability may be limited by (a) bankruptcy, insolvency, reorganization, moratorium or similar laws of general applicability affecting the enforcement of creditors&#8217; rights and (b) the application of general principles of equity (regardless of whether such enforceability is considered in a proceeding in equity or at law).&nbsp;&nbsp;This Amendment (x) does not require any consent or approval of, registration or filing with, or any other action by, any Governmental Authority or any third party, except for such as have been obtained or made and are in full force and effect, (y) will not violate any applicable law or regulation or the charter, bylaws or other organizational documents of the Borrower and its Subsidiaries or any order of any Governmental Authority, other than any such violations that, individually or in the aggregate, could not reasonably be expected to have a Material Adverse Effect, (z) will not violate or result in an event of default under any material indenture, agreement or other instrument binding upon the Borrower and its Subsidiaries or assets, or give rise to a right thereunder to require any payment to be made by any such Person.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">(ii)<font style="margin-left:36pt;"></font>No Default or Event of Default has occurred or is continuing or will result after giving effect to this Amendment.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a>(iii)<font style="margin-left:36pt;"></font>The representations and warranties made by or with respect to the Borrower in <font style="font-weight:bold;">Section 7</font> of the Loan Agreement are (A) in the case of representations qualified by &#8220;materiality,&#8221; &#8220;Material Adverse Effect&#8221; or similar language, true and correct in all respects and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">234986339 v1</strike></font><font style="font-size:12pt;color:#000000;"> </font></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">(B) in the case of all other representations and warranties, true and correct in all material respects (except that the representation regarding representations and warranties that refer to a specific earlier date are true and correct on the basis set forth above as of such earlier date), in each case taking into account any changes made to schedules updated in accordance with </font><font style="font-weight:bold;">Section 7.20</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"> of the Loan Agreement or attached hereto</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">(iv)<font style="margin-left:36pt;"></font>There has been no Material Adverse Effect since the date of the Loan Agreement.</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">SECTION 6.<font style="margin-left:36pt;"></font>Reaffirmation<font style="font-weight:normal;">. Each Obligor hereby ratifies, confirms, reaffirms, and acknowledges its obligations under the Loan Documents to which it is a party and agrees that the Loan Documents remain in full force and effect, undiminished by this Amendment, except as expressly provided herein.&nbsp;&nbsp;By executing this Amendment, Borrower acknowledges that it has read, consulted with its attorneys regarding, and understands, this Amendment.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">SECTION 7.<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman Bold;">Release</font><font style="font-weight:normal;">.&nbsp;&nbsp;In consideration of the agreements of Administrative Agent and the Lenders contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Borrower, on behalf of itself and its successors, assigns and other legal representatives, hereby fully, absolutely, unconditionally and irrevocably releases, remises and forever discharges Administrative Agent and each Lender, and their respective successors and assigns, and their respective present and former shareholders, affiliates, subsidiaries, divisions, predecessors, directors, officers, attorneys, employees, agents and other representatives (Administrative Agent, each Lender and all such other persons being hereinafter referred to collectively as the &#8220;</font><font style="font-style:italic;">Releasees</font><font style="font-weight:normal;">&#8221; and individually as a &#8220;</font><font style="font-style:italic;">Releasee</font><font style="font-weight:normal;">&#8221;), of and from all demands, actions, causes of action, suits, covenants, contracts, controversies, agreements, promises, sums of money, accounts, bills, reckonings, damages and any and all other claims, counterclaims, defenses, rights of set-off, demands and liabilities whatsoever of every name and nature, known or unknown, suspected or unsuspected, both at law and in equity, which Borrower or any of its successors, assigns or other legal representatives may now or hereafter own, hold, have or claim to have against the Releasees or any of them for, upon or by reason of any circumstance, action, cause or thing whatsoever which arises at any time on or prior to the day and date of this Amendment, including, without limitation, for or on account of, or in relation to, or in any way in connection with the Loan Agreement or any of the other Loan Documents or transactions thereunder or related thereto (collectively, the &#8220;</font><font style="font-style:italic;">Released Claims</font><font style="font-weight:normal;">&#8221;).&nbsp;&nbsp;Borrower understands, acknowledges and agrees that the release set forth above (the &#8220;</font><font style="font-style:italic;">Release</font><font style="font-weight:normal;">&#8221;) may be pleaded as a full and complete defense and may be used as a basis for an injunction against any action, suit or other proceeding which may be instituted, prosecuted or attempted in breach of the provisions of the Release.&nbsp;&nbsp;Borrower agrees that no fact, event, circumstance, evidence or transaction which could now be asserted or which may hereafter be discovered shall affect in any manner the final, absolute and unconditional nature of the Release.&nbsp;&nbsp;Borrower acknowledges that the Release constitutes a material inducement to Administrative Agent and the Lenders to enter into this Amendment and that Administrative Agent and the Lenders would not have done so but for Administrative Agent&#8217;s and each Lender&#8217;s expectation that the Release is valid and enforceable in all events.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">234986339 v1</strike></font><font style="font-size:12pt;color:#000000;"> </font></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a><font style="font-weight:bold;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">SECTION 8.</font><font style="margin-left:36pt;"></font><font style="font-family:Times New Roman Bold;">Governing Law; Submission to Jurisdiction</font><font style="font-variant: small-caps;">; Waiver of Jury Trial</font><font style="font-weight:normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Governing Law</font>.&nbsp;&nbsp;This Amendment and the rights and obligations of the parties hereunder shall be governed by, and construed in accordance with, the law of the State of New York, without regard to principles of conflicts of laws that would result in the application of the laws of any other jurisdiction; <font style="font-style:italic;">provided that</font> Section 5-1401 of the New York General Obligations Law shall apply.</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">(b)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Submission to Jurisdiction</font>.&nbsp;&nbsp;Borrower agrees that any suit, action or proceeding with respect to this Amendment or any other Loan Document to which it is a party or any judgment entered by any court in respect thereof may be brought initially in the federal or state courts in Houston, Texas or in the courts of its own corporate domicile and irrevocably submits to the non-exclusive jurisdiction of each such court for the purpose of any such suit, action, proceeding or judgment.&nbsp;&nbsp;This <font style="font-weight:bold;">Section 8</font> is for the benefit of Administrative Agent and the Lenders only and, as a result, none of Administrative Agent or any Lender shall be prevented from taking proceedings in any other courts with jurisdiction.&nbsp;&nbsp;To the extent allowed by applicable Laws, Administrative Agent and the Lenders may take concurrent proceedings in any number of jurisdictions.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">(c)<font style="margin-left:433pt;"></font><font style="font-weight:bold;font-family:Times New Roman Bold;font-variant: small-caps;">Waiver of Jury Trial</font>.&nbsp;&nbsp;<font style="font-variant: small-caps;">Borrower, Administrative Agent and each Lender hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any suit, action or proceeding arising out of or relating to this Amendment, the other Loan Documents or the transactions contemplated hereby or thereby.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">SECTION 9.<font style="margin-left:36pt;"></font>Miscellaneous<font style="font-weight:normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">No Waiver</font>.&nbsp;&nbsp;Except as expressly stated herein, nothing contained herein shall be deemed to constitute a waiver of compliance with any term or condition contained in the Loan Agreement or any of the other Loan Documents or constitute a course of conduct or dealing among the parties.&nbsp;&nbsp;Except as expressly stated herein, Administrative Agent and the Lenders reserve all rights, privileges and remedies under the Loan Documents.&nbsp;&nbsp;Except as amended hereby, the Loan Agreement and other Loan Documents remain unmodified and in full force and effect.&nbsp;&nbsp;All references in the Loan Documents to the Loan Agreement shall be deemed to be references to the Loan Agreement as amended hereby.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">(b)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Severability</font>.&nbsp;&nbsp;In case any provision of or obligation under this Amendment shall be invalid, illegal or unenforceable in any jurisdiction, the validity, legality and enforceability of the remaining provisions or obligations, or of such provision or obligation in any other jurisdiction, shall not in any way be affected or impaired thereby.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">(c)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Headings</font>.&nbsp;&nbsp;Headings and captions used in this Amendment (including the Exhibits, Schedules and Annexes hereto, if any) are included for convenience of reference only and shall not be given any substantive effect.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU5"></a>(d)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Integration</font>.&nbsp;&nbsp;This Amendment constitutes a Loan Document and, together with the other Loan Documents, incorporates all negotiations of the parties hereto with respect to the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">234986339 v1</strike></font><font style="font-size:12pt;color:#000000;"> </font></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">subject matter hereof and is the final expression and agreement of the parties hereto with respect to the subject matter hereof.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">(e)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Counterparts</font>.&nbsp;&nbsp;This Amendment may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument and any of the parties hereto may execute this Amendment by signing any such counterpart.&nbsp;&nbsp;Executed counterparts delivered by facsimile or other electronic transmission (e.g., &#8220;PDF&#8221; or &#8220;TIF&#8221;) shall be effective as delivery of a manually executed counterpart.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">(f)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Controlling Provisions</font>.&nbsp;&nbsp;In the event of any inconsistencies between the provisions of this Amendment and the provisions of any other Loan Document, the provisions of this Amendment shall govern and prevail.&nbsp;&nbsp;Except as expressly modified by this Amendment, the Loan Documents shall not be modified and shall remain in full force and effect.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> [Remainder of page intentionally left blank]</p>
<p style="text-align:center;margin-top:12pt; clear:both;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</a></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">234986339 v1</strike></font><font style="font-size:12pt;color:#000000;"> </font></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU6"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IN WITNESS WHEREOF, the parties hereto have duly executed this Amendment as of the date first above written.</font></p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BORROWER:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EYEPOINT PHARMACEUTICALS, INC.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By <font style="text-decoration:underline;">/s/George Elston</font><font style="text-decoration:underline;margin-left:36pt;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;Name: George Elston</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;Title: Chief Financial Officer</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GUARANTORS:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EYEPOINT PHARMACEUTICALS US, INC.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By <font style="text-decoration:underline;">/s/George Elston</font><font style="text-decoration:underline;margin-left:36pt;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;Name: George Elston</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;Title: Chief Financial Officer</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ICON BIOSCIENCE, INC.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By <font style="text-decoration:underline;">/s/Philip Hoffstein</font><font style="text-decoration:underline;margin-left:36pt;"></font> </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;Name: Philip Hoffstein</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;Title: President</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:50%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">[Signature Page to Amendment No. 2 and Waiver]</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU7"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ADMINISTRATIVE AGENT:</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:46.15%;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CRG SERVICING LLC</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By <font style="text-decoration:underline;">/s/Nathan Hukill</font><font style="text-decoration:underline;margin-left:36pt;"></font> </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;margin-right:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name: Nathan Hukill</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;margin-right:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title: Authorized Signatory</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LENDERS:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:30.77%;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CRG PARTNERS IV L.P.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:2.88%;margin-right:30.77%;text-indent:3.85%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By: CRG PARTNERS IV GP L.P.,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:2.88%;margin-right:30.77%;text-indent:3.85%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">its general partner</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;margin-right:30.77%;text-indent:3.85%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By: CRG PARTNERS IV GP LLC,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;margin-right:30.77%;text-indent:3.85%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">its general partner</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;margin-right:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;margin-right:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_1642"></a>By: <font style="text-decoration:underline;">/s/Nathan Hukill</font><font style="text-decoration:underline;margin-left:36pt;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:46.15%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">Name:<font style="margin-left:36pt;">Nathan Hukill</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:46.15%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">Title:<font style="margin-left:36pt;">Sole Member</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:20.09%;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_1662"></a>CRG<font style="text-transform:uppercase;"> PARTNERS IV &#8211; </font>PARALLEL FUND &#8220;C&#8221; (CAYMAN) L.P.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;margin-right:9.62%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_1661"></a>By: CR GROUP L.P.,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;margin-right:9.62%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">its investment advisor</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;margin-right:46.15%;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;margin-right:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_1665"></a>By: <font style="text-decoration:underline;">/s/Nathan Hukill</font><font style="text-decoration:underline;margin-left:36pt;"></font> </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:46.15%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:<font style="margin-left:36pt;">Nathan Hukill</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:46.15%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:<font style="margin-left:36pt;">Authorized Signatory</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Witness: <font style="text-decoration:underline;">/s/</font><font style="text-decoration:underline;Background-color:#FFFFFF;color:#000000;">Nicole Nesson</font><font style="text-decoration:underline;Background-color:#FFFFFF;color:#000000;margin-left:36pt;"></font> </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name: <font style="text-decoration:underline;Background-color:#FFFFFF;color:#000000;"> Nicole Nesson</font><font style="text-decoration:underline;Background-color:#FFFFFF;color:#000000;margin-left:36pt;"></font> </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:21.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:20.09%;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CRG<font style="text-transform:uppercase;"> PARTNERS IV &#8211; </font>CAYMAN LEVERED L.P.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;margin-right:9.62%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By: CRG PARTNERS IV (CAYMAN) GP L.P.,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;margin-right:9.62%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">its general partner</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;margin-right:9.62%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By: CRG PARTNERS IV GP LLC,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;margin-right:9.62%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Its general partner</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;margin-right:46.15%;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;margin-right:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By: <font style="text-decoration:underline;">/s/Nathan Hukill</font><font style="text-decoration:underline;margin-left:36pt;"></font> </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;margin-right:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:<font style="margin-left:36pt;">Nathan Hukill</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:46.15%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:<font style="margin-left:36pt;">Authorized Signatory</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Witness: <font style="text-decoration:underline;">/s/</font><font style="text-decoration:underline;Background-color:#FFFFFF;color:#000000;"> Nicole Nesson</font><font style="text-decoration:underline;Background-color:#FFFFFF;color:#000000;margin-left:36pt;"></font><br />Name: <font style="text-decoration:underline;Background-color:#FFFFFF;color:#000000;"> Nicole Nesson</font><font style="text-decoration:underline;Background-color:#FFFFFF;color:#000000;margin-left:36pt;"></font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">[Signature Page to Amendment No. 2 and Waiver]</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>eypt-ex991_6.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
eypt-ex991_6.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Cambria;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="goh5qhzuy4u2000001.jpg" title="" alt="" style="width:294px;height:59px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Calibri;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">EyePoint Pharmaceuticals <font style="color:#000000;">Announces Amendment to CRG Debt Facility Modifying 2020 and 2021 Revenue Covenants</font></p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WATERTOWN, Mass., October 8, 2020 -&#160;EyePoint Pharmaceuticals, Inc.&#160;(NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced an amendment to its existing debt facility with CRG Servicing LLC (CRG). Under the terms of the amendment, CRG has waived the covenant associated with the Company&#8217;s net product revenue of DEXYCU&#174; and YUTIQ&#174; for the twelve-month period ending on December 31, 2020. The parties also agreed to a reduction of the December 31, 2021 net product revenue covenant to $45 million from $80 million based on the promising recovery and return in customer demand for both products following COVID-19-related closures. There were no other material changes made to the term loan agreement with CRG.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;This amendment recognizes the encouraging recovery trends of customer demand and commercial progress as additional U.S. regions re-open for business following COVID-19-related closures,&#8221; said George Elston, Chief Financial Officer and Head of Corporate Development of EyePoint Pharmaceuticals. &#8220;We appreciate the support of our partners at CRG as we continue to expand the reach of our product portfolio to patients in need.&#8221;&nbsp;&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;We are happy to support our portfolio companies through the challenges of this year. More importantly, we are pleased with the recent commercial progress, encouraging customer demand trends and future outlook as customer facilities return to normal operations,&#8221; said Luke D&#252;ster, Partner, CRG. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company drew an initial $35 million under the debt facility in February 2019. In April 2019, the Company exercised its option to borrow an additional $15 million under the terms of the loan. Prior to the conclusion of the debt facility&#8217;s five-year term, the Company is required to make interest-only payments.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At September 30, 2020 the Company had approximately $28.7 million of cash.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">About CRG</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CRG is a premier healthcare-focused investment firm with nearly $4 billion of assets under management. The firm seeks to commit between $20.0 to $300.0 million in companies across the healthcare spectrum, including: medical devices, biopharmaceuticals, tools &amp; diagnostics, services and information technology. CRG provides growth capital in the form of long-term debt and equity to support innovative, commercial-stage healthcare companies that address large, unmet medical needs. The firm partners with public and private companies to provide flexible financing solutions and world-class support to achieve exceptional growth objectives with minimal dilution. CRG maintains offices in Boulder, New York and Houston. For more information, please visit www.crglp.com.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">About&#160;EyePoint Pharmaceuticals</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EyePoint Pharmaceuticals, Inc. (www.eyepointpharma.com) is a pharmaceutical company committed to developing and commercializing innovative ophthalmic products in indications with high unmet medical need to help improve the lives of patients with serious eye disorders. The Company currently has two commercial products: DEXYCU&#174;, the first approved intraocular product for the treatment of postoperative inflammation, and YUTIQ&#174;, a three-year treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The Company's pipeline leverages its proprietary bioerodible Durasert&#174; technology for extended intraocular drug delivery including EYP-1901, a potential six-month anti-VEGF therapy initially targeting wet age-related macular degeneration. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts with offices in Basking Ridge, New Jersey. To learn more about the Company, please visit www.eyepointpharma.com and connect on Twitter and LinkedIn.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a>SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION ACT OF 1995: Various statements made in this release are forward-looking, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we intend, expect, plan or believe may occur in the future, including but not limited to statements about our expectations regarding the extent to which our business could be adversely impacted by the effects of the COVID-19 coronavirus pandemic, as well as the timing and clinical development of our product candidates, including EYP-1901; and the potential for EYP-1901 as a vital, novel six-month treatment for serious eye diseases, including wet age-related macular degeneration, diabetic retinopathy and retinal vein occlusion. Some of the factors that could cause actual results to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements are risks and uncertainties inherent in our business including, without limitation: the extent to which COVID-19 impacts our business; the effectiveness and timeliness of clinical trials, and the usefulness of the data; the timeliness of regulatory approvals; our ability to achieve profitable operations and access to needed capital; fluctuations in our operating results; our ability to successfully produce sufficient commercial quantities of YUTIQ and DEXYCU and to successfully commercialize YUTIQ and DEXYCU in the U.S.; our ability to sustain and enhance an effective commercial infrastructure and enter into and maintain commercial agreements for YUTIQ and DEXYCU; the development of our YUTIQ line extension shorter-duration treatment for non-infectious uveitis affecting the posterior segment of the eye; potential off-label sales of ILUVIEN for non-infectious uveitis affecting the posterior segment of the eye; consequences of fluocinolone acetonide side effects for YUTIQ; consequences of dexamethasone side effects for DEXYCU; successful commercialization of, and receipt of revenues from, ILUVIEN for diabetic macular edema, or DME; Alimera&#8217;s ability to obtain additional marketing approvals and the effect of pricing and reimbursement decisions on sales of ILUVIEN for DME; Alimera&#8217;s ability to commercialize ILUVIEN for non-infectious uveitis affecting the posterior segment of the eye in the territories in which Alimera is licensed to do so; our ability to market and sell products; the success of current and future license agreements, including our agreement with Equinox Science; termination or breach of current license agreements, including our agreement with Equinox Science; our dependence on contract research organizations, contract sales organizations, vendors and investigators; effects of competition and other developments affecting sales of products; market acceptance of products; effects of guidelines, recommendations and studies; protection of intellectual property and avoiding intellectual property infringement; retention of key personnel; product liability; industry consolidation; compliance with environmental laws; manufacturing risks; risks and costs </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of international business operations; volatility of stock price; possible dilution; absence of dividends; and other factors described in our filings with the Securities and Exchange Commission. We cannot guarantee that the results and other expectations expressed, anticipated or implied in any forward-looking statement will be realized. A variety of factors, including these risks, could cause our actual results and other expectations to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements. Should known or unknown risks materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected in the forward-looking statements. You should bear this in mind as you consider any forward-looking statements. Our forward-looking statements speak only as of the dates on which they are made. We do not undertake any obligation to publicly update or revise our forward-looking statements even if experience or future changes makes it clear that any projected results expressed or implied in such statements will not be realized.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Contacts</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investors:<br />Argot Partners</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sam Martin or Joe Rayne </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">212-600-1902 </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">eyepoint@argotpartners.com</font> <font style="color:#000000;"> </font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Media:<br />Thomas Gibson</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">201-476-0322<br /><font style="text-decoration:underline;color:#000000;">tom@tomgibsoncommunications.com&nbsp;&nbsp; </font> </p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>goh5qhzuy4u2000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 goh5qhzuy4u2000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  \ 2<# 2(  A$! Q$!_\0
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ML-UM"97WCIC&P?G12VEZ"CLS1^.O_'AH_P#UV?\ D*]-L/\ D7K;_KT7_P!
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MZD^KI<E;'[*9B5.P;0-ORCYO6MS4=3U#3=8\+M=PW5Q.UK,+B"U&XL^U.<9
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MD.G>(]1\5^.(]#U*1/L5M=M,JQ(%9C&Q*Y/IQVQ7KU*HGI<)!11169(4444
+%%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>eypt-20201008.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2020-10-07T22:08:34.5086892+00:00 -->
<!-- Version            : 5.0.1.513 -->
<!-- Package ID         : a25b535ff2524c3eb3c4bdb2d68560cf -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:eypt="http://eyepointpharma.com/20201008" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://eyepointpharma.com/20201008" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" namespace="http://xbrl.sec.gov/country/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd" namespace="http://xbrl.sec.gov/currency/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2019-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd" namespace="http://xbrl.sec.gov/exch/2020-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/negated" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/net" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" namespace="http://fasb.org/srt/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd" namespace="http://fasb.org/srt-roles/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" namespace="http://fasb.org/srt-types/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" namespace="http://xbrl.sec.gov/stpr/2018-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" namespace="http://fasb.org/us-gaap/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd" namespace="http://fasb.org/us-roles/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" namespace="http://fasb.org/us-types/2020-01-31" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType id="TemplateLink" roleURI="http://eyepointpharma.com/20201008/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="eypt-20201008_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="eypt-20201008_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://eyepointpharma.com/20201008/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>eypt-20201008_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2020-10-07T22:08:34.5086892+00:00 -->
<!-- Version            : 5.0.1.513 -->
<!-- Package ID         : a25b535ff2524c3eb3c4bdb2d68560cf -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd#axisDefault" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-commencement Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-commencement Issuer Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>eypt-20201008_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2020-10-07T22:08:34.5086892+00:00 -->
<!-- Version            : 5.0.1.513 -->
<!-- Package ID         : a25b535ff2524c3eb3c4bdb2d68560cf -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://eyepointpharma.com/20201008/role/TemplateLink" xlink:href="eypt-20201008.xsd#TemplateLink" xlink:type="simple" />
  <link:roleRef roleURI="http://eyepointpharma.com/20201008/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="eypt-20201008.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20201008/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>eypt-8k_20201008_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="eypt-20201008.xsd" xlink:type="simple"/>
    <context id="C_0001314102_20201008_20201008">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
        </entity>
        <period>
            <startDate>2020-10-08</startDate>
            <endDate>2020-10-08</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="C_0001314102_20201008_20201008" id="F_000001">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="C_0001314102_20201008_20201008" id="F_000004">0001314102</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="C_0001314102_20201008_20201008" id="F_000000">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="C_0001314102_20201008_20201008" id="F_000002">2020-10-08</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="C_0001314102_20201008_20201008" id="F_000003">EyePoint Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="C_0001314102_20201008_20201008" id="F_000015">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="C_0001314102_20201008_20201008" id="F_000007">000-51122</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="C_0001314102_20201008_20201008" id="F_000008">26-2774444</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="C_0001314102_20201008_20201008" id="F_000009">480 Pleasant Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="C_0001314102_20201008_20201008" id="F_000010">Watertown</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="C_0001314102_20201008_20201008" id="F_000011">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="C_0001314102_20201008_20201008" id="F_000012">02472</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="C_0001314102_20201008_20201008" id="F_000013">(617)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="C_0001314102_20201008_20201008" id="F_000014">926-5000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="C_0001314102_20201008_20201008" id="F_000018">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="C_0001314102_20201008_20201008" id="F_000019">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="C_0001314102_20201008_20201008" id="F_000020">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="C_0001314102_20201008_20201008" id="F_000021">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="C_0001314102_20201008_20201008" id="F_000016">Common Stock, par value $0.001</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="C_0001314102_20201008_20201008" id="F_000005">EYPT</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="C_0001314102_20201008_20201008" id="F_000017">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="C_0001314102_20201008_20201008" id="F_000006">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140382485769128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Oct. 08, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Oct.  08,  2020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">EyePoint Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001314102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EYPT<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-51122<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-2774444<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">480 Pleasant Street<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Watertown<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02472<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(617)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">926-5000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( +8X2%$'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " "V.$A1<:0VS>X    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+;
M2L0P$(9?17+?3MKU1.CF1O%*07!!\2XDL[O!YD RTN[;F];=+J(/X&5F_GSS
M#4RGH] AX7,*$1-9S!>CZWT6.J[9GB@*@*SWZ%2N2\*7YC8DIZ@\TPZBTA]J
MA]!R?@T.21E%"B9@%1<BDYW10B=4%-(1;_2"CY^IGV%& _;HT%.&IFZ R6EB
M/(Q]!V? !"-,+G\7T"S$N?HG=NX .R;';)?4, SUL)IS98<&WIX>7^9U*^LS
M*:^Q_,I6T"'BFITFOZ[N[C</3+:\Y57#*WZ[X3>"7XG+]GUR_>%W%G;!V*W]
MQ\8G0=G!K[N07U!+ P04    " "V.$A1F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M +8X2%$=:[2D/P0  $P0   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MG9A1<^(V$,>?KY]"P_3A;B:)+04"N2',$)*TF;LD7."::3M]$/8"FMB6*\LA
M?/NN#+&YG%DSS4.PL?;OGU;2?R7Z*VV>LR6 9:]QE&07K:6UZ6?/RX(EQ#([
MT2DD^&2N32PMWIJ%EZ4&9%@$Q9$G?/_,BZ5*6H-^\=W8#/HZMY%*8&Q8EL>Q
M-.M+B/3JHL5;;U\\JL72NB^\03^5"YB _9Z.#=YYI4JH8D@RI1-F8'[1&O+/
MEZ+M HH6?RA893O7S'5EIO6SN[D-+UJ^(X(( NLD)'Z\P BBR"DAQ[];T5;Y
M3A>X>_VF?E-T'CLSDQF,=/2D0KN\:/5:+(2YS"/[J%>_P[9#':<7Z"@K_K/5
MIFV[W6)!GED=;X.1(%;)YE.^;A.Q$W#*]P2(;8 HN#<O*BBOI)6#OM$K9EQK
M5',715>+:(13B1N5B37X5&&<'5SI(,<D6R:3D%TG5MDUNTTVHXU9ZWL67^*:
M>L%6\'(C*/8(/@3VA/F](R9\X?\8[B%;"2A*0%'HG>[1&^D7,.SOX2RS!H?P
M'T+RM)0\+23;37V>KE.HZR$=WCO^0D"T2X@VJ3)$@K"@N(GDHHZ"CI_+* ."
MHU-R= Y+QAB,TFX.A QG4FU>:*5BY'M'OWSXT##T9R7:&2FXG8Z/L%!N\)'Q
M7L:U8 TZ:QAKY;JXE#BO \BM"C!]1SC3@Q,"M%N"=@\!'6$:C8Q0-817]@76
M=:BTDN_[_)2WN2\(K%Z)U2/%ID:&*EFPR3J>Z:@.AHZ__G,\)3#.2XSS0[)S
M'8-9.)S?,-XNV4C'J4QJ<T3K-<U\[E?>YQ]"=J,B8/=Y/ -3ZW>T" [9<8=S
M08T8W[%C?@C25+ZRVQ#GDYKC5"WJ%P%(2XJS8]'MMO&/(JS\F(M#"(=A:"##
M-;2]8%^Q'7M(:M=G@V2[Y[-Q!#)S:QP?8#&C4"N?Y[13OT<=N3MMV%2OZBL;
M+?>$MFCL3[$_PE7^SVD#?P\WL2COZ,9&OZ@DJ$\DK7DWI-"JDL!I)W^/-M:9
M15_[2Z6X:L-Z,%K1%^TNN4"JFL!I,R_&<(@;T/THM,#',][]1*%4KL]IL_ZJ
ML8I@4=$):1^TR#DNSPYZ"$54&3YO<.RW#5R@3:I-81P[,VND<ZQ0Z_V9H]6O
MKBG(JAQPVK^GRJ+?ZCGCXN/L$YM D!NDK@6BE;"$Q.B,$ZN#YR.62L->9)0#
M^]4_P3I*;3ZK$B%H=W^C8]>OP5(F"]B[!VD0NA].KH;?**:J1@C:T)\0R$+B
M*FB<)]OZD-4RT4)-E53L;-)I!Y_H2 7*NO)^YUQ2R=K]1H-*(T_E_(*VZK&!
MXP#3 ^BCFZT^[K;Q'/$PG]>OT@:]1K+*]@5MT3^1W699CF2-@/_S..#MG W=
M.?M.NEU8QB*8HY!_TD7C-INCZ^;&ZK0X+LZTQ<-G<;G$XSX8UP"?S[6V;S?N
M!%K^@##X#U!+ P04    " "V.$A1@ZFE ]0!   R!@  #0   'AL+W-T>6QE
M<RYX;6S55=N*U$ 0_96F/\">1'9!20(J+ @J"SL/OG:22M+0-SN5,=FOMSN=
MV[@,J ^B+Y,ZIZI/G;Y.UN,DX:D#0#(JJ?N<=HCV+6-]U8'B_2MC0?M,8YSB
MZ*%K66\=\+H/@Y1DZ>ETSQ07FA:9'M2#PIY49M"8TQ-E1=88O3.O:21\*5=
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M,:@W6]5C6)>E:H\_A?<HN9\;[O\2Q0]02P,$%     @ MCA(49>*NQS
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M=1,92L88!.R '<(Y_<Z[5ITPX1X=\G>A^[<#K3P&]'@!6^A<JU3'\TLDO,3
MQFU+BLX5>C(,=D",Y1]XVXG\-/O4(VSV'T:$%'J6"V&%E+C?Z/F-:#R!+ ]=
MR_$)'0.M#,,SQ;;!<.AHQ$5V9://8:Q#B'/Z3XRQJK"$52Q;#X&'' E<)S"D
M&IND53 >"CVN*!.L>@PL(:EU&*ADMW,JI]=V<,TB]RI#FJ,,:&T'X:-:"Q4&
ML&]R( DNR94;4EWI>::W=Y-[2:AU[D&P]_ :C1W-CQ^W_ %02P,$%     @
MMCA(420>FZ*M    ^ $  !H   !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L
M<[61/0Z#, R%KQ+E #50J4,%3%U8*RX0!?,C$A+%K@JW+X4!D#IT8;*>+7_O
MR4Z?:!1W;J"V\R1&:P;*9,OL[P"D6[2*+L[C,$]J%ZSB688&O-*]:A"2*+I!
MV#-DGNZ9HIP\_D-T==UI?#C]LCCP#S"\7>BI160I2A4:Y$S":+8VP5+BRTR6
MHJ@R&8HJEG!:(.+)(&UI5GVP3TZTYWD7-_=%KLWC":[?#'!X=/X!4$L#!!0
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M&G_FB^$_7G\!4$L! A0#%     @ MCA(40=!36*!    L0   !
M     ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " "V.$A1<:0V
MS>X    K @  $0              @ &O    9&]C4')O<',O8V]R92YX;6Q0
M2P$"% ,4    " "V.$A1F5R<(Q &  "<)P  $P              @ ', 0
M>&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( +8X2%$=:[2D/P0  $P0
M   8              " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q0
M2P$"% ,4    " "V.$A1@ZFE ]0!   R!@  #0              @ &"#
M>&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( +8X2%&7BKL<P    !,"   +
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4!08     "0 ) #X"   %$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>95</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="eypt-8k_20201008.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20201008/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="eypt-8k_20201008.htm">eypt-8k_20201008.htm</File>
    <File>eypt-20201008.xsd</File>
    <File>eypt-20201008_lab.xml</File>
    <File>eypt-20201008_pre.xml</File>
    <File>eypt-ex101_7.htm</File>
    <File>eypt-ex991_6.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "eypt-8k_20201008.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "definitionLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "eypt-8k_20201008.htm"
     ]
    },
    "labelLink": {
     "local": [
      "eypt-20201008_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "eypt-20201008_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "eypt-20201008.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 95,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "eypt",
   "nsuri": "http://eyepointpharma.com/20201008",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "eypt-8k_20201008.htm",
      "contextRef": "C_0001314102_20201008_20201008",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://eyepointpharma.com/20201008/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "eypt-8k_20201008.htm",
      "contextRef": "C_0001314102_20201008_20201008",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://eyepointpharma.com/20201008/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://eyepointpharma.com/20201008/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://eyepointpharma.com/20201008/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "verboseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://eyepointpharma.com/20201008/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line1",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://eyepointpharma.com/20201008/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://eyepointpharma.com/20201008/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://eyepointpharma.com/20201008/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://eyepointpharma.com/20201008/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://eyepointpharma.com/20201008/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://eyepointpharma.com/20201008/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://eyepointpharma.com/20201008/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://eyepointpharma.com/20201008/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://eyepointpharma.com/20201008/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://eyepointpharma.com/20201008/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://eyepointpharma.com/20201008/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://eyepointpharma.com/20201008/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://eyepointpharma.com/20201008/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security12b Title",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://eyepointpharma.com/20201008/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://eyepointpharma.com/20201008/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://eyepointpharma.com/20201008/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://eyepointpharma.com/20201008/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://eyepointpharma.com/20201008/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001564590-20-046049-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-20-046049-xbrl.zip
M4$L#!!0    ( +8X2%'$2] _N 0  ,46   1    97EP="TR,#(P,3 P."YX
M<V2]6%MOVS84?A^P_\#JJ<6JJ^/4-I(4V=P !MRL<+*A;P5-4391BM)(*K'_
M?4G*E&5;=BTEG5]"\=P^GAMY<O5QE5+PA+D@&;MV0B]P &8HBPE;7#N%<*%
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M_A5:-AO1E!T#4$I.YH7$=QE/QSB!!56F"O9? 2E)"(Y59Z18M[4=AAI90K[
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M[KB16^I?_"2[</QO;\[_!U!+ P04    " "V.$A1@VL7]@(%  #D*P  %0
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M6+/Q>HTY[?9_P4AEL&\9/S%1[>M5!NXFHFH"Q<4')1?)%%;P&(OT-)P'3%0
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M2Q/?U1H?\H7!X<NQV.$&4>+Y5?<KR=<Q]*2.$?L<$AK<(U6+>O'W>9WB/1.
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MHF$AKB6I%W\G0VXC_7)).*9:6["8ODLD'P>V3QWF!M*>$ GJK1Q.5,NH@3N
MM0RUWB@W0LSB<0'T(T"T3^*RH6O#X-@.G?L<;5Y)]B1CY MSF("MH>- VT!Y
M>LBI5M9"<#$2/PU8Q:L14A$N=!16>F(0ZPF!JZ0)EXXDU;3#PP_'=R/NLR*.
MC6MW)ZBW@E%[&)/*BY'#<M&0F<":8[.F)US5:M67FG VJ_38C<O(MP[I3<8@
M]UZ<54X ;"<&=)UPY&[9*1_T'X+[P*'H-0J<R.*4SPNW#5S7'E!@31\$!%)
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M.(7_#V(E, ES&L<SN)6&V^I^ ?54W'+,+$!7 4G!]9F:/T -#QRK&(%XKOX
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M;QY7.BD-7&NB9C_RQS;\^']02P,$%     @ MCA(4:/]3O&-&P  [<,  !
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M_HQ Y1"[BQ2+'$&>G\P\_D [4JZ<+#7UFMP]T('@+DJ+]QSE(V89B[Q.B"*
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M'Z"">9&:)7H8WE5=X(I;@50ENGCI ?>Y."F,5(\%5[\"PN;;JGTN9H6^IS'
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M3]+4K&B*P[,7QT?=X6[7JI2U':7&E58YWK%58D7_Y$9@/&;,\ Y\ %!,9+Z
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M="TR,#(P,3 P."YX<V102P$"% ,4    " "V.$A1GBS_[A<'  "*20  %0
M            @ 'G!   97EP="TR,#(P,3 P.%]L86(N>&UL4$L! A0#%
M  @ MCA(48-K%_8"!0  Y"L  !4              ( !,0P  &5Y<'0M,C R
M,#$P,#A?<')E+GAM;%!+ 0(4 Q0    ( +8X2%%O,&GOO1,  (RF   4
M          "  681  !E>7!T+3AK7S(P,C Q,# X+FAT;5!+ 0(4 Q0    (
M +8X2%&C_4[QC1L  .W#   0              "  54E  !E>7!T+65X,3 Q
M7S<N:'1M4$L! A0#%     @ MCA(4;8,S[2H$   !D$  !
M ( !$$$  &5Y<'0M97@Y.3%?-BYH=&U02P4&      8 !@"# 0  YE$

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
